Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Crescent City Research Consortium, LLC
mi
from
Marrero, LA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Crescent City Research Consortium, LLC
mi
from
Marrero, LA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland- St Joseph's Medical Center
mi
from
Towson, MD
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland- St Joseph's Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
St. Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Center
mi
from
Detroit, MI
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
The University of Kansas Cancer Center
mi
from
Kansas City, MO
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
The University of Kansas Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Cancer Center
mi
from
Hershey, PA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Cancer Center
mi
from
Hershey, PA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of the Carolinas/ITOR
mi
from
Greenville, SC
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of the Carolinas/ITOR
mi
from
Greenville, SC
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Sciences Center
mi
from
San Antonio, TX
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Tyler, TX
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Tyler, TX
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Tyler, TX
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Tyler, TX
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
UMASS Memorial Medical Center
mi
from
Worcester, MA
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
UMASS Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado School of Medicine - Division of Medical Oncology
mi
from
Aurora, CO
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado School of Medicine - Division of Medical Oncology
mi
from
Aurora, CO
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Hartford Healthcare Cancer Institute at Midstate Medical Center
mi
from
Meriden, CT
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Hartford Healthcare Cancer Institute at Midstate Medical Center
mi
from
Meriden, CT
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Ottawa Hospital Cancer Center
mi
from
Ottawa,
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Ottawa Hospital Cancer Center
mi
from
Ottawa,
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Clinical Oncology Program
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
The University of Arizona Cancer Center - North Campus
mi
from
Tucson, AZ
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
The University of Arizona Cancer Center - North Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Study of WT2725 in Patients With Advanced Malignancies
Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Denver, CO
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital
mi
from
Hartford, CT
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University
mi
from
Washington,
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Lombardi Comprehensive Cancer Center at Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic Medical Center
mi
from
Burlington, MA
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/31/1969
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/31/1969
University of Michigan University Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials